Sara Louise Weisenbach, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Apathy | 2 | 2021 | 96 | 1.440 |
Why?
|
| Depressive Disorder | 6 | 2020 | 3747 | 1.400 |
Why?
|
| Depressive Disorder, Major | 19 | 2020 | 4639 | 1.290 |
Why?
|
| Facial Expression | 7 | 2017 | 508 | 0.760 |
Why?
|
| Cognition | 8 | 2018 | 6770 | 0.760 |
Why?
|
| Depression | 8 | 2021 | 7759 | 0.730 |
Why?
|
| Emotions | 11 | 2018 | 2659 | 0.700 |
Why?
|
| Neuropsychological Tests | 18 | 2020 | 6994 | 0.700 |
Why?
|
| Hydrocortisone | 4 | 2018 | 1826 | 0.550 |
Why?
|
| Dementia, Vascular | 2 | 2014 | 129 | 0.550 |
Why?
|
| Pituitary-Adrenal System | 2 | 2018 | 553 | 0.540 |
Why?
|
| Verbal Learning | 3 | 2015 | 468 | 0.530 |
Why?
|
| Aging | 5 | 2018 | 8664 | 0.510 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2018 | 703 | 0.510 |
Why?
|
| Bipolar Disorder | 6 | 2018 | 5027 | 0.470 |
Why?
|
| Neurobiology | 1 | 2014 | 121 | 0.460 |
Why?
|
| Motivation | 2 | 2021 | 1971 | 0.450 |
Why?
|
| Semantics | 5 | 2018 | 585 | 0.430 |
Why?
|
| Gait | 1 | 2015 | 793 | 0.350 |
Why?
|
| Cerebrovascular Disorders | 1 | 2016 | 1504 | 0.350 |
Why?
|
| Memory, Short-Term | 1 | 2014 | 977 | 0.310 |
Why?
|
| Public Health | 1 | 2021 | 2602 | 0.310 |
Why?
|
| Cognition Disorders | 6 | 2020 | 4043 | 0.300 |
Why?
|
| Age of Onset | 4 | 2015 | 3270 | 0.300 |
Why?
|
| Association Learning | 3 | 2018 | 224 | 0.290 |
Why?
|
| Cerebral Cortex | 6 | 2018 | 5709 | 0.280 |
Why?
|
| Executive Function | 5 | 2020 | 1364 | 0.270 |
Why?
|
| Brain Mapping | 10 | 2017 | 6670 | 0.260 |
Why?
|
| Neurodegenerative Diseases | 1 | 2014 | 1061 | 0.260 |
Why?
|
| Cues | 4 | 2018 | 875 | 0.240 |
Why?
|
| Mood Disorders | 4 | 2021 | 1106 | 0.240 |
Why?
|
| Alzheimer Disease | 3 | 2021 | 8038 | 0.210 |
Why?
|
| Amygdala | 4 | 2017 | 1315 | 0.210 |
Why?
|
| Attention | 4 | 2015 | 2397 | 0.200 |
Why?
|
| Concept Formation | 1 | 2021 | 158 | 0.180 |
Why?
|
| Reaction Time | 2 | 2018 | 2098 | 0.180 |
Why?
|
| Memory Disorders | 3 | 2019 | 1186 | 0.180 |
Why?
|
| Antidepressive Agents | 3 | 2020 | 2838 | 0.170 |
Why?
|
| Prefrontal Cortex | 3 | 2018 | 2147 | 0.170 |
Why?
|
| Brain | 10 | 2018 | 26388 | 0.170 |
Why?
|
| Psychomotor Performance | 2 | 2019 | 1901 | 0.170 |
Why?
|
| Memory | 3 | 2018 | 2174 | 0.170 |
Why?
|
| Young Adult | 19 | 2019 | 56429 | 0.160 |
Why?
|
| Mental Recall | 2 | 2015 | 1206 | 0.160 |
Why?
|
| Humans | 43 | 2023 | 744366 | 0.160 |
Why?
|
| Dopamine | 3 | 2012 | 1591 | 0.160 |
Why?
|
| Case-Control Studies | 8 | 2018 | 21748 | 0.150 |
Why?
|
| Saliva | 2 | 2018 | 809 | 0.150 |
Why?
|
| Aged | 19 | 2021 | 163288 | 0.150 |
Why?
|
| Quality of Life | 2 | 2017 | 12802 | 0.140 |
Why?
|
| Neural Pathways | 5 | 2017 | 2974 | 0.140 |
Why?
|
| Acetylcholine | 2 | 2010 | 621 | 0.140 |
Why?
|
| Sex Characteristics | 3 | 2017 | 2585 | 0.130 |
Why?
|
| Social Adjustment | 1 | 2017 | 631 | 0.130 |
Why?
|
| Neostriatum | 1 | 2016 | 250 | 0.130 |
Why?
|
| Rest | 2 | 2017 | 901 | 0.120 |
Why?
|
| Gyrus Cinguli | 3 | 2018 | 1091 | 0.120 |
Why?
|
| Longevity | 2 | 2020 | 1071 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 17 | 2018 | 35425 | 0.120 |
Why?
|
| Male | 28 | 2020 | 350115 | 0.110 |
Why?
|
| Adolescent | 13 | 2018 | 85779 | 0.110 |
Why?
|
| Limbic System | 1 | 2016 | 426 | 0.110 |
Why?
|
| Female | 30 | 2020 | 380193 | 0.110 |
Why?
|
| Analysis of Variance | 4 | 2016 | 6366 | 0.110 |
Why?
|
| Face | 3 | 2017 | 994 | 0.110 |
Why?
|
| Adult | 20 | 2020 | 214052 | 0.110 |
Why?
|
| Social Perception | 1 | 2016 | 425 | 0.110 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 57776 | 0.100 |
Why?
|
| Middle Aged | 21 | 2018 | 213390 | 0.100 |
Why?
|
| Functional Laterality | 3 | 2013 | 2290 | 0.100 |
Why?
|
| Cushing Syndrome | 1 | 2011 | 249 | 0.090 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2012 | 475 | 0.090 |
Why?
|
| Photic Stimulation | 2 | 2012 | 2026 | 0.080 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2019 | 2305 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2019 | 5077 | 0.080 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2018 | 1433 | 0.080 |
Why?
|
| Personality | 1 | 2012 | 552 | 0.080 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 13991 | 0.080 |
Why?
|
| Walking | 1 | 2015 | 1180 | 0.080 |
Why?
|
| Synaptic Transmission | 2 | 2012 | 1178 | 0.080 |
Why?
|
| Geriatric Assessment | 1 | 2015 | 1372 | 0.080 |
Why?
|
| Lewy Body Disease | 1 | 2010 | 229 | 0.080 |
Why?
|
| Acetylcholinesterase | 2 | 2005 | 153 | 0.070 |
Why?
|
| Adaptation, Psychological | 1 | 2017 | 2575 | 0.070 |
Why?
|
| Pattern Recognition, Visual | 1 | 2013 | 824 | 0.070 |
Why?
|
| Frontal Lobe | 1 | 2013 | 1406 | 0.070 |
Why?
|
| Reward | 1 | 2012 | 940 | 0.060 |
Why?
|
| Risk Factors | 4 | 2020 | 72296 | 0.060 |
Why?
|
| Regression Analysis | 4 | 2017 | 6459 | 0.060 |
Why?
|
| Agnosia | 1 | 2005 | 66 | 0.060 |
Why?
|
| Social Support | 1 | 2014 | 2118 | 0.060 |
Why?
|
| Basal Nucleus of Meynert | 1 | 2004 | 27 | 0.060 |
Why?
|
| Cholinergic Fibers | 1 | 2004 | 68 | 0.060 |
Why?
|
| Cost of Illness | 1 | 2014 | 1860 | 0.060 |
Why?
|
| Parkinson Disease | 2 | 2010 | 2775 | 0.060 |
Why?
|
| Hippocampus | 1 | 2016 | 3675 | 0.060 |
Why?
|
| Multiple Sclerosis | 1 | 2017 | 3079 | 0.050 |
Why?
|
| Life Style | 1 | 2014 | 3835 | 0.050 |
Why?
|
| Exercise | 1 | 2019 | 5615 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2016 | 8949 | 0.050 |
Why?
|
| Tomography, Emission-Computed | 1 | 2004 | 1144 | 0.050 |
Why?
|
| Dihydroxyphenylalanine | 2 | 2010 | 76 | 0.040 |
Why?
|
| Oxygen | 3 | 2016 | 4189 | 0.040 |
Why?
|
| Comorbidity | 1 | 2012 | 10388 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2020 | 6036 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2020 | 281 | 0.040 |
Why?
|
| Austria | 1 | 2017 | 202 | 0.040 |
Why?
|
| Family Relations | 1 | 2017 | 321 | 0.030 |
Why?
|
| Mastication | 1 | 2014 | 53 | 0.030 |
Why?
|
| Sex Factors | 2 | 2019 | 10400 | 0.030 |
Why?
|
| Computers | 1 | 2017 | 612 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2020 | 2618 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 2017 | 651 | 0.030 |
Why?
|
| Acetates | 2 | 2005 | 311 | 0.030 |
Why?
|
| Remission Induction | 1 | 2019 | 2385 | 0.030 |
Why?
|
| Individuality | 1 | 2015 | 307 | 0.030 |
Why?
|
| Self Concept | 1 | 2017 | 1025 | 0.020 |
Why?
|
| Malingering | 1 | 2011 | 77 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 2018 | 1670 | 0.020 |
Why?
|
| Lewy Bodies | 1 | 2010 | 137 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2011 | 648 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2004 | 6254 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2010 | 2016 | 0.020 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2015 | 1953 | 0.020 |
Why?
|
| Patient Selection | 1 | 2020 | 4216 | 0.020 |
Why?
|
| Psychotherapy | 1 | 2017 | 1642 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 15535 | 0.020 |
Why?
|
| Acoustic Stimulation | 1 | 2011 | 1216 | 0.020 |
Why?
|
| Piperidines | 2 | 2005 | 1602 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 39052 | 0.020 |
Why?
|
| Haplotypes | 1 | 2012 | 2779 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2018 | 8319 | 0.020 |
Why?
|
| Perception | 1 | 2011 | 1198 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2005 | 1157 | 0.020 |
Why?
|
| Carbon Radioisotopes | 1 | 2004 | 577 | 0.010 |
Why?
|
| Positron-Emission Tomography | 2 | 2010 | 6234 | 0.010 |
Why?
|
| Medical History Taking | 1 | 2005 | 784 | 0.010 |
Why?
|
| Atrophy | 1 | 2005 | 1584 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 2011 | 2624 | 0.010 |
Why?
|
| Genotype | 1 | 2012 | 12952 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2010 | 4042 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2011 | 9145 | 0.010 |
Why?
|
| Prognosis | 1 | 2017 | 29060 | 0.010 |
Why?
|
| Time Factors | 1 | 2015 | 40075 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 15520 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2017 | 53290 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2017 | 63107 | 0.010 |
Why?
|
| United States | 1 | 2017 | 69872 | 0.010 |
Why?
|